AUSTIN, Texas, September 22, 2025 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels.
The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments.
To begin the interview, Dr. Trieu provided an overview of the company’s mission and therapeutic scope.
“Oncotelic is a clinical-stage biotechnology company. We’re developing drugs to treat cancer and other rare diseases such as Parkinson’s and sexual dysfunction,” he said. “The team has been around for about 25 years. We originally developed Abraxane and, later, Cynviloq, and now we’re working on a lot of exciting drugs around oncology.”
He then discussed how Oncotelic’s development approach sets the company apart in the biotech space.
“What we have at Oncotelic is a really deep knowledge of the tumor microenvironment, as well as the regulatory pathway that we develop for each one of the drugs. When we take on an asset, we can easily build IP around it and protect it. Then, we push it out through a regulatory pathway that has the shortest timeline and highest chance of approval. That really differentiates us from everyone else.”
Looking ahead, Dr. Trieu outlined the key inflection points investors should watch.
“Our investors should be really looking forward to a lot of announcements from us in the next 12 months or so, both from the clinical side… as well as regulatory milestones such as IND approval, expansion into other indications, and partnership announcements… The team has been really focusing on operational execution—getting these drugs moving through clinical development, into trials, and toward approval.”
Join IBN’s Carmel Fisher for a conversation with Dr. Vuong Trieu, Chairman and CEO of Oncotelic Therapeutics, to learn more about the company’s differentiated clinical pipeline and forward-looking development strategy.
To hear the episode and subscribe for future podcasts, visit https://podcast.biomedwire.com
The latest installment of The BioMedWire Podcast continues to reinforce IBN’s commitment to the expansion of its robust network of brands, client partners, followers, and the growing IBN Podcast Series. For more than 19 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to 500+ public and private companies.
To learn more about IBN’s achievements and milestones via a visual timeline, visit: https://IBN.fm/TimeLine
About Oncotelic Therapeutics
Oncotelic Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The company’s mission is to address high-unmet-need cancers and rare pediatric indications with innovative, late-stage therapeutic candidates.
In addition to its directly owned and developed drug pipeline, Oncotelic benefits from the robust portfolio of inventions created by its CEO, Dr. Vuong Trieu, who has filed over 150 patent applications and holds 39 issued U.S. patents. Beyond its internal programs, the company also licenses and co-develops select drug candidates through joint ventures. Currently, Oncotelic owns 45% of GMP Bio, a joint venture under Dr. Trieu’s leadership and guidance, which is advancing its own pipeline of drug candidates that further complement and strengthen Oncotelic’s strategic position in oncology and rare disease therapeutics.
For more information, visit the company’s website at www.Oncotelic.com
About IBN
IBN consists of financial brands introduced to the investment public over the course of 19+ years. With IBN, we have amassed a collective audience of milli
Popular Podcasts
Las Culturistas with Matt Rogers and Bowen Yang
Ding dong! Join your culture consultants, Matt Rogers and Bowen Yang, on an unforgettable journey into the beating heart of CULTURE. Alongside sizzling special guests, they GET INTO the hottest pop-culture moments of the day and the formative cultural experiences that turned them into Culturistas. Produced by the Big Money Players Network and iHeartRadio.
Crime Junkie
Does hearing about a true crime case always leave you scouring the internet for the truth behind the story? Dive into your next mystery with Crime Junkie. Every Monday, join your host Ashley Flowers as she unravels all the details of infamous and underreported true crime cases with her best friend Brit Prawat. From cold cases to missing persons and heroes in our community who seek justice, Crime Junkie is your destination for theories and stories you won’t hear anywhere else. Whether you're a seasoned true crime enthusiast or new to the genre, you'll find yourself on the edge of your seat awaiting a new episode every Monday. If you can never get enough true crime... Congratulations, you’ve found your people. Follow to join a community of Crime Junkies! Crime Junkie is presented by audiochuck Media Company.
The Brothers Ortiz
The Brothers Ortiz is the story of two brothers–both successful, but in very different ways. Gabe Ortiz becomes a third-highest ranking officer in all of Texas while his younger brother Larry climbs the ranks in Puro Tango Blast, a notorious Texas Prison gang. Gabe doesn’t know all the details of his brother’s nefarious dealings, and he’s made a point not to ask, to protect their relationship. But when Larry is murdered during a home invasion in a rented beach house, Gabe has no choice but to look into what happened that night. To solve Larry’s murder, Gabe, and the whole Ortiz family, must ask each other tough questions.